Chromosome Engineering Research Center, Tottori University, 86 Nishi-cho, Yonago, Tottori, 683-8503, Japan.
Department of Chromosome Biomedical Engineering, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori, 683-8503, Japan.
Sci Rep. 2023 Mar 14;13(1):4225. doi: 10.1038/s41598-023-31263-x.
We previously generated fully human antibody-producing TC-mAb mice for obtaining potential therapeutic monoclonal antibodies (mAbs). In this study, we investigated 377 clones of fully human mAbs against a tumor antigen, epithelial cell adhesion molecule (EpCAM), to determine their antigen binding properties. We revealed that a wide variety of mAbs against EpCAM can be obtained from TC-mAb mice by the combination of epitope mapping analysis of mAbs to EpCAM and native conformational recognition analysis. Analysis of 72 mAbs reacting with the native form of EpCAM indicated that the EpCL region (amino acids 24-80) is more antigenic than the EpRE region (81-265), consistent with numerous previous studies. To evaluate the potential of mAbs against antibody-drug conjugates, mAbs were directly labeled with DM1, a maytansine derivative, using an affinity peptide-based chemical conjugation (CCAP) method. The cytotoxicity of the conjugates against a human colon cancer cell line could be clearly detected with high-affinity as well as low-affinity mAbs by the CCAP method, suggesting the advantage of this method. Thus, this study demonstrated that TC-mAb mice can provide a wide variety of antibodies and revealed an effective way of identifying candidates for fully human ADC therapeutics.
我们之前通过生成能够产生全人源抗体的 TC-mAb 小鼠来获得潜在的治疗性单克隆抗体 (mAbs)。在这项研究中,我们研究了 377 株针对肿瘤抗原上皮细胞黏附分子 (EpCAM) 的全人源 mAbs,以确定它们的抗原结合特性。我们揭示了通过对 mAbs 与 EpCAM 的表位作图分析和天然构象识别分析的组合,可以从 TC-mAb 小鼠中获得针对 EpCAM 的各种 mAbs。对与天然形式 EpCAM 反应的 72 株 mAbs 的分析表明,EpCL 区域(氨基酸 24-80)比 EpRE 区域(81-265)更具抗原性,这与许多先前的研究一致。为了评估针对抗体药物偶联物的 mAbs 的潜力,我们使用基于亲和肽的化学偶联 (CCAP) 方法直接将 DM1(一种美登素衍生物)标记到 mAbs 上。通过 CCAP 方法,高亲和力和低亲和力 mAbs 对人结肠癌细胞系的细胞毒性都可以清晰地检测到,这表明了该方法的优势。因此,本研究表明 TC-mAb 小鼠可以提供各种抗体,并揭示了一种鉴定全人源 ADC 治疗候选物的有效方法。